Synthetic study of phomoidride B (CP-263,114); utilization of the oxidopyrylium [5 + 2] cycloaddition

Naoki Ohmori

Department of Chemistry, Graduate School of Science, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima 739-8526, Japan. E-mail: d1174001@hiroshima.u.ac.jp

Received (in Cambridge, UK) 15th May 2001, Accepted 28th June 2001 First published as an Advance Article on the web 1st August 2001

The highly functionalized core structure of phomoidride B (CP-263,114) was pursued by using intermolecular oxidopyrylium–alkene cyclization as one of the key steps.

In 1997, the group of Kaneko reported the structure of phomoidride B (1) and its hydrolysed derivatives, both showing inhibitory activity towards farnesyl transferase¹ with IC_{50} values in the micromolar range.² A great many synthetic organic chemists have been attracted by its fascinating structural features and so far four groups have achieved elegant complete total syntheses.³ Retrosynthetic analysis suggested that 1 could be accessed from 2 by introducing side chains followed by minimal functional group manipulations. Bicyclic 2 in turn could be constructed from modestly functionalized seven-membered ring 3, which could easily be obtained by treating the oxidopyrylium ylide⁴ 4 with fumarate ester or its variants thus providing easy access to the maleic anhydride moiety of the CP-core (Scheme 1).



Scheme 1 Strategy for the total synthesis of phomoidride B (1).

The synthesis began with the protection of but-2-ene-1,4-diol with TBSCl (Scheme 2). Oxidopyrylium precursor **8** was easily prepared in 5 steps (39% from but-2-ene-1,4-diol). When using dimethyl fumarate as the alkene, cyclization took place quite efficiently in the presence of Et_3N to deliver oxabicycles **9a** and **9b** (13:1) in 77% combined yield. Hydrogenation of **9a**



Scheme 2 Reagents and conditions: (a) TBSCl, Et₃N, DMAP, THF, rt; (b) O₃, MeOH, -78 °C, then NaHCO₃, Me₂S, -78 °C \rightarrow rt, quant. (2 steps); (c) 2-lithiofuran, Et₂O, -78 °C \rightarrow rt; (d) MCPBA, CH₂Cl₂, 0 °C \rightarrow rt; (e) Ac₂O, pyridine, rt, 39% (3 steps); (f) dimethyl fumarate, Et₃N, CH₃CN, reflux, 77% (**9a**:**9b**, 13:1).

followed by the removal of the silyl protecting group and iodination gave 12 (Scheme 3). Of several attempts to cleave the ether bridge in reductive fashion, Zn proved to be the most suitable, yielding exo-enone 13 in 96% yield. Homologation of the exo olefin seemed reasonable for introducing the lacking two carbon unit required for construction of the bicyclo-[4.3.1]decene core. To this end, 13 was treated with TBSOTf in the presence of 2,6-lutidine to give a separable mixture of TBSprotected acetal 14 (49%) and enone 15 (5%). Acetal 14 was next converted to 16[†] in two steps by allylation in the presence of TiCl₄ followed by reprotection of the liberated alcohol with TBSOTf. Ketone 16 was subjected to ozonolysis to yield a ketoaldehyde, which was subsequently treated with DBU to promote the intramolecular aldol reaction.⁶ The crude aldol adduct was oxidized with PCC to deliver diketones 17a and 17b (4:1, 82% yield over 2 steps). Oxidation of 17a to enone 18 under Saegusa's conditions⁷ proceeded in 35% yield. Improved yields were obtained using the recently reported Nicolaou method using IBX (IBX = 2-iodylbenzoic acid),⁸ giving enone 18 in 30% yield along with recovery of the starting material (42%). Repeated oxidation of recovered 17a resulted in a combined yield of 42% (52%, based on recovered 17a). Lewis acid catalyzed allylation of 18 gave a 1,4-adduct as a single stereoisomer. Further allylation utilizing palladium chemistry



Scheme 3 Reagents and conditions: (a) H₂, Pd/C, MeOH, rt; (b) aq. HCl, rt; (c) I₂, PPh₃, imidazole, benzene, reflux, 64% (3 steps); (d) Zn, MeOH, reflux, 96%; (e) TBSOTf, 2,6-lutidine, CH₂Cl₂, -78 °C, 54% (14:15, 10:1); (f) allyltrimethylsilane, TiCl₄, CH₂Cl₂, -78 °C; (g) TBSOTf, 2,6-lutidine, CH₂Cl₂, -78 °C; (g) TBSOTf, 2,6-lutidine, CH₂Cl₂, rt, 66% (2 steps); (h) O₃, MeOH, then NaHCO₃, Me₂S, -78 °C \rightarrow rt, 81%; (i) DBU, CH₂Cl₂; (j) PCC, CH₂Cl₂, 4 Å MS, rt, 82% (2 steps, 17a: 17b, 4:1); (k) IBX, DMSO–PhMe (1:2), 80 °C, 52%; (l) allyltrimethylsilane, TiCl₄, CH₂Cl₂, -78 °C, 57%; (m) KHMDS, allyl chloroformate, THF, -78 °C, 63%; (n) Pd₂(dba)₃-CHCl₃, PPh₃, THF, rt, 81% (19:20, 2:1).

DOI: 10.1039/b104268h



Scheme 4 Reagents and conditions: (a) Br_2 , CH_2Cl_2 , -40 °C, then Et_3N , -40 °C \rightarrow rt; 99%; (b) NaCN, Bu_4NI , CH_2Cl_2 — H_2O , rt, then Et_3N , rt, 97%; (c) Me_2S=CHCO_2Me, THF, 0 °C \rightarrow rt, 61%; (d) SmI_2, THF, -78 °C, 79%; (e) aq. HCl, 0 °C \rightarrow rt; (f) I₂, PPh₃, imidazole, benzene, reflux, 64% (2 steps); (g) Zn, Ac₂O, 50 °C, 25%.

delivered **19**[‡] (19% yield from **18**) a highly advanced bicyclic intermediate with the required relative stereochemistry between the bridging carbonyl group and the hydrophobic side-chain at C9 along with **20** (10% yield from **18**).

Having established a method for the construction of the bicyclic framework, we then focussed upon the quaternary carbon centre adjacent to the bridgehead. To this end **9a** was first converted to **21** in 2 steps (96%) (Scheme 4). Various attempts to produce directly the desired quaternary centre with organometal reagents were unsuccessful, probably due to the highly functionalized nature of **21**. Only by using a sulfonium ylide did the reaction take place without any problems, furnishing a cyclopropane product **22**. Reductive cleavage of **22** with SmI₂ proceeded with complete regioselectivity to generate the required quaternary centre.§ Compound **23** was next deprotected under acidic conditions followed by iodination to give **25**. Zinc reduction and protection of the resultant hydroxy group with an acetyl group gave **26**.¶

We are currently exploring methods to complete the fully functionalized core and modify the side chains *en route* to phomoidride B.

I am grateful to Professor K. Ohkata for his valuable advice and to Dr S. Kojima for prereading of the manuscript. I am also grateful to Drs Y. Hiraga and R. Takagi for assistance in NMR.

Notes and references

 \dagger In this reaction **16** was obtained stereoselectively at the C2 centre. While the reason for this selectivity is unclear, it may be due to the proton delivering effect of the hydroxy group in the intermediate silyl enol ether during work-up (ref. 5).

‡ Although the C8 stereochemistry of **19** is not certain, **19** was obtained as the sole stereoisomer.

 $\$ Although SmI₂ has previously been used for cyclopropane opening (ref. 10), to our knowledge, regioselective opening of cyclopropane bearing electron stabilizing groups on all three carbons with SmI₂ is unprecedented.

¶ Data for 9a: $R_f = 0.39$ (silica gel, EtOAc-hexane 1:2); mp 92–94 °C (CH₂Cl₂); v_{max} (neat)/cm⁻¹ 2955, 1740, 1695; δ_{H} (500 MHz, CDCl₃) 7.34 (dd, J 9.8, 4.6, 1H, H-6), 6.02 (d, J 9.8, 1H, H-7), 5.19 (d, J 4.6, 1H, H-5), 4.25 (d, J11.9, 1H, H-8), 4.22 (d, J4.3, 1H, CHCO₂Me), 4.01 (d, J11.9, 1H, H-8), 3.76 (s, 3H, CO₂CH₃), 3.66 (s, 3H, CO₂CH₃), 3.61 (d, J 4.3, 1H, CHCO₂Me), 0.90 (s, 9H, Si-t-Bu), 0.11 (s, 3H, Si-Me) 0.70 (s, 3H, Si-Me); $\delta_{\rm C}$ (125 MHz, CDCl₃) 193.6, 171.0, 170.3, 150.7, 127.3, 91.7, 75.9, 60.3, 52.6, 52.4, 50.6, 46.6, 25.6, 18.1, -5.5, -5.7. HRMS (EI): calc. for C₁₈H₂₈O₇Si (M⁺): 384.1604. Found: 384.1588. Anal calc: C 56.23, H 7.34. Found: C 56.13, H 7.43%. For **26**: $R_{\rm f} = 0.53$ (silica gel, EtOAc-hexane 1:1); $v_{\text{max}}(\text{neat})/\text{cm}^{-1}$ 2955, 1740, 1440; δ_{H} (500 MHz, CDCl₃) 5.59 (br s, 1H, exo-CH2=), 5.09 (s, 1H, exo-CH2=), 4.99 (s, 1H, H-5), 4.23 (d, J7.0, 1H, CHCO₂Me), 3.81 (s, 3H, CO₂CH₃), 3.79 (s, 3H, CO₂CH₃), 3.77 (s, 3H, CO₂CH₃), 3.66 (dd, J 7.0, 1.8, 1H, CHCO₂Me), 3.08 (d, J 17.4, 1H, CH₂CO₂Me), 3.00 (d, J 17.4, 1H, CH₂CO₂Me), 2.89 (d, J 13.7, 1H, H-7), 2.62 (d, J 13.7, 1H, H-7), 2.11 (s, 3H, acetyl); δ_C (125 MHz, CDCl₃) 171.8, 171.5, 169.4, 167.6, 141.4, 119.8, 113.3, 104.9, 80.9, 53.1, 52.8, 52.3, 45.9, 45.5, 44.6, 43.1, 40.9, 21.6. HRMS (EI) calc. for C₁₈H₂₁O₉Si (M⁺): 395.1216. Found: 395.1212.

- Review: D. M. Leonard, J. Med. Chem., 1997, 40, 2971; K. Hinterding, D. Alonso-Díaz and H. Waldmann, Angew. Chem., Int. Ed., 1998, 37, 688.
- 2 T. T. Dabrah, T. Kaneko, W. Massefski, Jr. and E. B. Whipple, J. Am. Chem. Soc., 1997, 119, 1594; T. T. Dabrah, H. J. Harwood, Jr., L. H. Huang, N. D. Jankovich, T. Kaneko, J.-C. Li, S. Lindsey, P. M. Moshier, T. A. Subashi, M. Therrien and P. C. Watts, J. Antibiot., 1997, 50, 1.
- 3 K. C. Nicolaou, P. S. Baran, Y.-L. Zhong, H.-S. Choi, W. H. Yoon, Y. He and K. C. Fong, Angew. Chem., Int. Ed., 1999, **38**, 1669; K. C. Nicolaou, P. S. Baran, Y.-L. Zhong, K. C. Fong, Y. He, W. H. Yoon and H.-S. Choi, Angew. Chem., Int. Ed., 1999, **38**, 1676; K. C. Nicolaou, J. K. Jung, W. H. Yoon, Y. He, Y.-L. Zhong and P. S. Baran, Angew. Chem., Int. Ed., 2000, **39**, 1829; C. Chen, M. E. Layton, S. M. Sheehan and M. D. Shair, J. Am. Chem. Soc., 2000, **122**, 7424; N. Waizumi, T. Itoh and T. Fukuyama, J. Am. Chem. Soc., 2000, **122**, 7825; Q. Tan and S. J. Danishefsky, Angew. Chem., Int. Ed., 2000, **39**, 4509.
- 4 J. B. Hendrickson and J. S. Farina, J. Org. Chem., 1980, 45, 3359; P. A. Wender, K. D. Rice and M. E. Schnute, J. Am. Chem. Soc., 1997, 119, 7897.
- 5 R. Hara, T. Furukawa, Y. Horiguchi and I. Kuwajima, J. Am. Chem. Soc., 1996, **118**, 9186.
- 6 J. R. Tagat, M. S. Puar and S. W. McCombie, *Tetrahedron Lett.*, 1996, 37, 8463.
- 7 Y. Ito, T. Hirato and T. Saegusa, J. Org. Chem., 1978, 43, 1011.
- 8 K. C. Nicolaou, Y.-L. Zhong and P. S. Baran, J. Am. Chem. Soc., 2000, 122, 7596.
- J. Tsuji, I. Minami and I. Shimizu, Tetrahedron Lett., 1983, 24, 1793.
- 10 R. A. Batey and W. B. Motherwell, *Tetrahedron Lett.*, 1991, **32**, 6211.